C WorldWide Group Holding A S Sells 10,000 Shares of Krystal Biotech, Inc. $KRYS

C WorldWide Group Holding A S trimmed its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.7% in the 2nd quarter, Holdings Channel reports. The firm owned 57,809 shares of the company’s stock after selling 10,000 shares during the period. C WorldWide Group Holding A S’s holdings in Krystal Biotech were worth $21,486,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KRYS. Royal Bank of Canada lifted its holdings in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares during the period. AQR Capital Management LLC grew its holdings in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after acquiring an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares during the last quarter. Empowered Funds LLC purchased a new stake in Krystal Biotech during the first quarter valued at $218,000. Finally, Cetera Investment Advisers lifted its holdings in Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after acquiring an additional 2,255 shares during the period. Institutional investors own 86.29% of the company’s stock.

Insider Activity

In other news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,000 shares of company stock worth $17,558,270 over the last quarter. Insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Down 1.9%

Shares of Krystal Biotech stock opened at $351.26 on Wednesday. The company has a market capitalization of $10.40 billion, a price-to-earnings ratio of 44.02 and a beta of 0.54. The stock’s 50-day simple moving average is $349.01 and its 200-day simple moving average is $308.57. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. On average, equities analysts expect that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KRYS. Bank of America boosted their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. TD Cowen boosted their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup increased their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.